Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 11:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 698 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Resectable Clear all
Withdrawn Phase 1Phase 2 Interventional

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

NCT03697239
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma, Pancreatic Metastasis
Interventions
Ascorbic Acid, Paclitaxel protein-bound, Cisplatin, Gemcitabine
Drug
Lead sponsor
Hitendra Patel
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 19, 2026, 11:15 AM EDT
Terminated Phase 2 Interventional Results available

Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site

NCT05110781
View directory record Official record
Conditions
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions
Atezolizumab, Radiation Therapy, Therapeutic Conventional Surgery
Biological · Radiation · Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 19, 2026, 11:15 AM EDT
Suspended No phase listed Observational

Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With Locally Advanced Breast Cancer

NCT05547347
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Resectable Breast Carcinoma
Interventions
Magnetic Resonance Imaging, Mammogram, Ultrasound, Ultrasound-Guided Biopsy, Twinkle marker
Procedure · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 19, 2026, 11:15 AM EDT
Recruiting Phase 2 Interventional

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

NCT04302025
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib, Atezolizumab, SBRT, Resection, Chemotherapy, Divarasib
Drug · Procedure
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
38
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 11:15 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP (PRISM-TAMP)

NCT07477418
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms
Interventions
Gemcitabine Delivered by Transarterial Microperfusion
Combination Product
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Oct 19, 2026, 11:15 AM EDT
Recruiting No phase listed Observational

ctDNA Assay in Patients With Resectable Pancreatic Cancer

NCT05052671
View directory record Official record
Conditions
Pancreas Cancer
Interventions
Not listed
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 19, 2026, 11:15 AM EDT
Terminated Phase 3 Interventional

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

NCT01836432
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Carcinoma Non-resectable, Locally Advanced Malignant Neoplasm
Interventions
FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation, Gemcitabine, Capecitabine, Nab-Paclitaxel
Drug · Biological · Radiation
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
32
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 19, 2026, 11:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

NCT01545141
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
Interventions
Chemokin Modulatory Regimen (5 MU/m2), Chemokin Modulatory Regimen (10 MU/m2), Chemokin Modulatory Regimen (20 MU/m2)
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 19, 2026, 11:15 AM EDT
Recruiting Early Phase 1 Interventional

FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

NCT06472661
View directory record Official record
Conditions
Advanced Melanoma
Interventions
Echopulse or Echopulse HD, PolyICLC
Device · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 19, 2026, 11:15 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma

NCT06624475
View directory record Official record
Conditions
Basal Cell Carcinoma
Interventions
Nivolumab, Relatlimab plus Nivolumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Irvine, California • La Jolla, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 19, 2026, 11:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

NCT04198766
View directory record Official record
Conditions
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
Interventions
INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2)
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2033
U.S. locations
30
States / cities
Duarte, California • Glendale, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 19, 2026, 11:15 AM EDT
Recruiting Not applicable Interventional

Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients

NCT07125729
View directory record Official record
Conditions
Resectable Colorectal Carcinoma, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
Interventions
Biospecimen Collection, cfDNA or ctDNA Measurement, Electronic Health Record Review
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Goodyear, Arizona • Corona, California • Duarte, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 19, 2026, 11:15 AM EDT
Recruiting Phase 2 Interventional

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

NCT07069712
View directory record Official record
Conditions
Gastroesophageal Adenocarcinoma
Interventions
Sonesitatug Vedotin, Rilvegostomig, Trastuzumab Deruxtecan (T-DXd), Capecitabine, 5-Fluorouracil (5-FU), FLOT Chemotherapy, Calcium folinate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Newark, Delaware • Washington D.C., District of Columbia • Fairway, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 11:15 AM EDT
Completed Phase 1Phase 2 Interventional

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Tumors

NCT00003461
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Metastatic Cancer, Neuroblastoma
Interventions
surgical procedure, astatine At 211 monoclonal antibody 81C6
Procedure · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Oct 19, 2026, 11:15 AM EDT
Terminated Phase 2 Interventional

Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma

NCT02225496
View directory record Official record
Conditions
Oropharyngeal Cancer
Interventions
Transoral Robotic Surgery (TORS), Modified Barium Swallow (MBS), Questionnaires
Procedure · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 19, 2026, 11:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

NCT03496662
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
BMS-813160, Nivolumab, Gemcitabine, Nab-paclitaxel, Biopsy, Peripheral blood
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Oct 19, 2026, 11:15 AM EDT
Completed No phase listed Observational

Study of DNA in Blood Samples From Patients With Neuroblastoma

NCT00898391
View directory record Official record
Conditions
Disseminated Neuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma, Stage 4S Neuroblastoma
Interventions
laboratory biomarker analysis, polymerase chain reaction, polyacrylamide gel electrophoresis, DNA analysis
Other · Genetic
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 19, 2026, 11:15 AM EDT
Recruiting Phase 1 Interventional

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

NCT04722523
View directory record Official record
Conditions
Head and Neck Cancer, Head Cancer, Head Cancer Neck, Neck Cancer, Head and Neck Squamous Cell Carcinoma, HNSCC
Interventions
Cisplatin, Carboplatin, Docetaxel, Cetuximab, Cemiplimab, Surgical Resection of Primary +/- Neck Dissection, Post-operative radiation therapy, Paclitaxel
Drug · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 19, 2026, 11:15 AM EDT
Terminated Phase 2 Interventional

SWOG-9451, Combination Chemo & RT For Patients With Stage III/Stage IV Cancer of the Hypopharynx or Tongue

NCT00002735
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Induction chemotherapy, cisplatin, fluorouracil, low-LET cobalt-60 gamma ray therapy
Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
18
States / cities
Little Rock, Arkansas • Los Angeles, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 19, 2026, 11:15 AM EDT
Terminated Phase 2 Interventional Results available

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

NCT03844750
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Hepatectomy, Pembrolizumab, Vactosertib
Procedure · Biological · Drug
Lead sponsor
Chloe Atreya, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 19, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer

NCT00557492
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Avastin (bevacizumab), Gemzar (Gemcitabine), external beam radiotherapy
Drug · Radiation
Lead sponsor
Amer Zureikat
Other
Eligibility
18 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 19, 2026, 11:15 AM EDT
Terminated Phase 2 Interventional

Phase II Study of Pre-Operative Chemotherapy in Patients With Resectable Local-Regional Carcinoma of Esophagus

NCT00208936
View directory record Official record
Conditions
Esophageal Diseases
Interventions
Taxol, Cisplatin, 5-Fluorouracil, G-CSF
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 19, 2026, 11:15 AM EDT
Completed Not applicable Interventional

Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma

NCT00040911
View directory record Official record
Conditions
Brain Tumors, Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Lymphoma, Nausea, Vomiting, Neuroblastoma, Ovarian Cancer, Sarcoma
Interventions
electroacupuncture therapy, sham intervention, quality-of-life assessment
Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
5 Years to 35 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2013 · Synced Oct 19, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma

NCT00525915
View directory record Official record
Conditions
Esophageal Cancer, Gastroesophageal Cancer
Interventions
5-Fluorouracil, Oxaliplatin, Radiation Therapy, Surgery
Drug · Radiation · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 76 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Oct 19, 2026, 11:15 AM EDT